Ocugen, Inc. (OCGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ocugen, Inc. on February 9, 2026. The filing discloses the appointment of a new Chief Financial Officer (CFO) and Principal Financial Officer, effective immediately following the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Appointment: Rita Johnson-Greene was appointed as Chief Financial Officer and Principal Financial Officer, effective February 9, 2026.
- Executive Transition: Ramesh Ramachandran stepped down as Principal Financial Officer but will continue as Chief Accounting Officer and Principal Accounting Officer.
Compensation, Guidance, and Risks
The filing details the employment agreement for Ms. Johnson-Greene, which includes the following compensation terms:
- Base Salary: $440,000 annually.
- Target Bonus: Up to 45% of base salary, subject to performance criteria.
- Sign-on Bonus: $90,000 one-time payment, subject to repayment if employment ends before the one-year anniversary.
- Equity Grants: 750,000 stock options and 500,000 restricted stock units (RSUs) vesting annually over three years.
- Severance Provisions: In the event of termination without cause or resignation for good reason, the executive is eligible for 12 months of base salary continuation and COBRA premium payments. In the event of a change in control within a specified window, the executive is eligible for an additional 75% of the target annual bonus and full acceleration of unvested equity awards.
The filing does not contain forward-looking guidance, management commentary on business operations, or specific risk factors beyond standard employment agreement contingencies.
Key Facts for Investor Verification
- Verify the impact of the new CFO's background in regenerative medicine and biotech sales on Ocugen's strategic direction.
- Review the total cost of the new employment package, including the $90,000 sign-on bonus and equity grants, against the company's current cash position.
- Confirm the vesting schedule and exercise price of the 750,000 options granted to the new CFO.
- Assess the potential dilution from the grant of 500,000 RSUs and 750,000 options.